(Q27853360)
Statements
1 reference
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial (English)
1 reference
April 2016
0 references
17
0 references
4
0 references
452-63
0 references